Abstract: Embodiments of the invention employ methods and compositions for enhancing potency of immune cells that express one or more therapeutic proteins. In certain cases, the methods modulate expression of a CAR transgene in an immune cell, such as a T cell. Specific embodiments employ the exposure of cells and/or individuals to be treated with the cells with an effective amount of at least one agent that upregulates expression of the therapeutic protein, such as a mitogen, histone deacetylase inhibitor, and or DNA methyltransferase inhibitor.
Type:
Grant
Filed:
March 21, 2019
Date of Patent:
January 10, 2023
Assignee:
Baylor College of Medicine
Inventors:
Juan Fernando Vera Valdes, Malcolm Brenner, Usanarat Anurathapan
Abstract: Embodiments of the disclosure encompass systems, methods, and compositions related to selective advantages to somatic cells that harbor one or more particular genetic modifications. In particular embodiments, there is selective expansion of gene-targeted cells wherein the strategy involves deletion of an essential gene product that is replaced with targeted integration that also includes integration of a therapeutic transgene. The cells that harbor the replaced essential gene product, and thereby the therapeutic transgene, are selected for using pharmaceutical or nutritional agents that are linked to the function of the essential gene product.
Type:
Application
Filed:
November 20, 2020
Publication date:
January 5, 2023
Applicant:
Baylor College of Medicine
Inventors:
William Lagor, Ayrea Hurley, Kelsey Jarrett, Karl-Dimiter Bissing, Marco De Giorgi, Mia Furgurson
Abstract: The present disclosure provides a 3?UTR CRISPR-dCas13 Engineering System, and methods of using said system, that allows for the manipulation of the length of 3?untranslated regions by using gRNAs to guide catalytically dead Cas13 to sites upstream and/or downstream of the desired poly adenylation sites. One aspect of the disclosure provides a system for modifying the length a 3? untranslated region (UTR) of an mRNA transcript.
Type:
Application
Filed:
July 13, 2020
Publication date:
December 22, 2022
Applicants:
DUKE UNIVERSITY, BAYLOR COLLEGE OF MEDICINE
Abstract: Embodiments of the present disclosure pertain generally to head and neck squamous cell carcinomas (HNSCCs) related to human papillomavirus subtype 16 (HPV16) infections. More particularly, the present disclosure provides novel immunogenic epitopes from HPV16 E2, E6 and E7 antigens restricted by common human leukocyte antigen (HLA) alleles for the diagnosis and treatment of HNSCC. The HPV16 epitopes identified in the present disclosure can be used in combination with blockade of HPV16+ HNSCC-specific checkpoints for targeted immunotherapy.
Type:
Grant
Filed:
November 15, 2018
Date of Patent:
December 13, 2022
Assignees:
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, BAYLOR COLLEGE OF MEDICINE
Inventors:
Sri Krishna, Marshall Posner, Andrew Sikora, Karen Anderson
Abstract: Provided herein are methods of expanding CD161+ T cells. Also provided are methods and compositions for generating modified CD161+ T cells comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T cells are produced, expanded, and/or used in disease (e.g, cancer) treatments.
Type:
Application
Filed:
November 6, 2020
Publication date:
December 8, 2022
Applicant:
BAYLOR COLLEGE OF MEDICINE
Inventors:
Vanaja KONDURI, William K. DECKER, Matthew M. HALPERT, Meenakshi G. HEGDE, Nabil M. AHMED, Sujith K. JOSEPH
Abstract: The present disclosure concerns combination therapy for cancer thatutilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor; and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.
Type:
Application
Filed:
November 7, 2019
Publication date:
December 8, 2022
Applicant:
Baylor College of Medicine
Inventors:
Masataka Suzuki, Amanda Rosewell Shaw, Caroline Elaine Porter, Norihiro Watanabe, Malcolm K. Brenner, Andrew Sikora
Abstract: Embodiments of the disclosure include certain formulations for methods of treating urea cycle disorders. The methods encompass compositions that comprise benzoate and phenylbutyrate that may be at certain doses and have certain ratios of the components. The benzoate and phenylbutyrate may act synergistically in treatment of the urea cycle disorders, in particular embodiments.
Type:
Grant
Filed:
June 28, 2018
Date of Patent:
December 6, 2022
Assignee:
Baylor College of Medicine
Inventors:
Juan C. Marini, Sandesh Chakravarthy Sreenath Nagamani
Abstract: A Magnetic Resonance Imaging (MRI) enhancement agent includes a plurality of particles, each particle including: a metal core; a dielectric shell disposed on the metal core comprising at least one MRI contrast agent; and a metal shell disposed on the exterior surface of the dielectric shell that encapsulates the dielectric shell.
Type:
Grant
Filed:
September 15, 2017
Date of Patent:
November 22, 2022
Assignees:
WILLIAM MARSH RICE UNIVERSITY, BAYLOR COLLEGE OF MEDICINE
Inventors:
Nancy J. Halas, Ciceron Ayala-Orozco, Sandra Bishnoi, Luke Henderson, Oara Neumann, Robia Pautler, Peter Nordlander
Abstract: A method for predicting a hypoglycemic event or a hyperglycemic event includes (a) collecting one or more data streams, wherein at least one of the one or more data streams includes a glucose (GL) data stream corresponding to a user, (b) determining one or more features based on the one or more collected data streams, wherein at least one of the one or more features is distinct from each of the one or more data streams, (c) generating a prediction of whether or not a hypoglycemic event or a hyperglycemic event will occur by a prediction model based on the one or more features determined at (b), and (d) issuing an alert to the user in response to the prediction generated at (c) including a prediction that a hypoglycemic event or a hyperglycemic event will occur.
Type:
Application
Filed:
October 16, 2020
Publication date:
November 17, 2022
Applicants:
THE TEXAS A&M UNIVERSITY SYSTEM, BAYLOR COLLEGE OF MEDICINE
Inventors:
Madhav Erraguntla, Darpit K. Dave, Balakrishna Haridas, Daniel J. DeSalvo, Siripoom V. McKay, Mark Alan Lawley, Achu Geetha Byju
Abstract: The present disclosure concerns methods and compositions related to cancer treatment comprising targeting of SRC-3 in immune cells, including T cells such as T regulatory cells. The targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR ex vivo to produce cells suitable for adoptive cell transfer. In some cases, one or more agents that target SRC-3 are also administered to the individual and/or are exposed to the cells prior to administration.
Type:
Grant
Filed:
August 27, 2021
Date of Patent:
November 15, 2022
Assignee:
Baylor College of Medicine
Inventors:
Bert W. O'Malley, Sang Jun Han, David M. Lonard, Bryan Nikolai, Prashi Jain, Yosef Gilad, Clifford Dacso
Abstract: The present disclosure provides methods and compositions related to Natural Killer T cells that are engineered to knock down the expression of one or more endogenous major histocompatibility complex (MHC) gene. The present disclosure also provides engineered CAR NKT cells that resist rejection by allogeneic immune cells both in vitro and in vivo.
Type:
Application
Filed:
April 22, 2022
Publication date:
November 3, 2022
Applicant:
Baylor College of Medicine
Inventors:
Andras HECZEY, Bin LIU, Leonid METELITSA
Abstract: The present disclosure encompasses methods for generating cells or tissue from existing cells with one or more mutated variants of Yap. In specific embodiments, the disclosure regards treatment of existing cardiomyocytes with one or more mutated variants of Yap that causes them to divide and generate new cardiomyocytes. In specific cases, the mutated variant of Yap has serine-to-alanine substitutions at 1, 2, 3, 4, 5, 6, or more serines of Yap.
Type:
Grant
Filed:
March 14, 2018
Date of Patent:
November 1, 2022
Assignee:
Baylor College of Medicine
Inventors:
Tanner Monroe, John Leach, James F. Martin
Abstract: A method of improving electrical conduction across an impaired region of a tissue (e.g., myocardial tissue), includes applying an electrically conductive wiring carbon nanotube fibers) across the impaired region. The electrically conductive wiring can become associated with non-impaired regions of the tissue on opposite sides of the impaired region by suturing. The method can also be utilized to treat or prevent cardiac arrhythmia in a subject (e.g., ventricular arrhythmia). The electrically conductive wiring includes carbon nanotubes, such as carbon nanotube fibers, Such electrically conductive wiring can be used to transmit electrical signals to a tissue or sense electrical signals from the tissue. Suture threads including carbon nanotubes, such as carbon nanotube fibers, are provided.
Type:
Application
Filed:
July 11, 2022
Publication date:
October 27, 2022
Applicants:
William Marsh Rice University, Baylor College of Medicine, Texas Heart Institute
Inventors:
Matteo Pasquali, Mehdi Razavi, Flavia Vitale, Colin Christopher Young, Mark David McCauley
Abstract: One aspect of the invention provides a method of generating bacteriophages adapted to infect a target bacterial strain. The method comprises: providing host bacteria that are susceptible to phage as input to a host chemostat containing phage; providing target bacteria that are related to the host bacteria, but not susceptible to phage as input to a target chemostat containing phage; filtering outflows from the host chemostat and the target chemostat to isolate phage from the populations of the host bacteria, the target bacteria, and macromolecules; combining the outflows; and introducing the combined outflow into each of the host chemostat and the target chemostat.
Abstract: Some embodiments are directed to a transcatheter and serially-expandable artificial heart valve, e.g., to be minimally-invasively implanted into a pediatric patient during a first procedure, and then expanded during a second procedure to accommodate for the pediatric patient's growth. Some embodiments include an expandable frame having a compressed, delivery configuration, and an expanded, deployed configuration, in which the valve is implantable within the patient. The valve can have a first working condition when the frame is expanded to a first diameter and a second working condition when the frame is expanded to a second diameter greater than the first diameter. The valve can include a plurality of leaflets configured to accommodate the expansion of the frame and growth of the patient.
Type:
Grant
Filed:
September 13, 2021
Date of Patent:
October 11, 2022
Assignees:
Baylor College of Medicine, William Marsh Rice University
Inventors:
Henri Justino, Daniel Harrington, Kwonsoo Chun
Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.
Type:
Grant
Filed:
November 12, 2020
Date of Patent:
October 4, 2022
Assignee:
BAYLOR COLLEGE OF MEDICINE
Inventors:
James F. Martin, Yuka Morikawa, Todd Ryan Heallen, John Leach
Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
Type:
Grant
Filed:
May 23, 2018
Date of Patent:
October 4, 2022
Assignee:
Baylor College of Medicine
Inventors:
Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
Abstract: Compositions and methods relating to regulation of gene expression are described. In some embodiments, the present disclosure provides compositions and methods for the regulation of gene expression using nucleic acid constructs. In some embodiments, the present disclosure recognizes the utility of alternative splicing in regulation of gene expression in a nucleic acid construct. In some embodiments, the present disclosure recognizes the utility of regulating gene expression utilizing ligand-binding aptamers.
Type:
Application
Filed:
August 28, 2020
Publication date:
September 15, 2022
Applicants:
Baylor College of Medicine, Baylor College of Medicine
Abstract: The present disclosure relates to machine-learning generalization, and in particular to techniques for regularizing machine-learning The present disclosure relates to machine-learning generalization, and in particular to techniques for regularizing machine-learning models using biological systems (e.g. brain data) to engineer machine-learning-algorithms that can generalize better. Particularly, aspects are directed to a computer implemented method that includes measuring a plurality of biological responses (e.g. neural responses to stimuli or other variables such body movements); generating data (e.g. responses to stimuli) using the predictive model which can denoise biological data and extract task relevant information; scaling and transforming these predictions (e.g. measure representational similarities between stimuli); and using the biologically derived data to regularize machine-learning-algorithms.
Type:
Application
Filed:
September 24, 2020
Publication date:
September 8, 2022
Applicants:
BAYLOR COLLEGE OF MEDICINE, UNIVERSITY OF TUBINGEN
Inventors:
ANDREAS TOLIAS, ZHE LI, ZACHARY PITKOW, JOSUE ORTEGA CARO, ANKIT PATEL, JACOB REIMER, MATTHIAS BETHGE, FABIAN SINZ
Abstract: The present disclosure relates to methods for screening test samples or substances that are capable of inducing or reducing nucleolar hypertrophy in cancer cells. The present disclosure further provides methods of contacting isolated cancer cells with a test sample or a substance that can induce nucleolar hypertrophy in a cancer cell. The present disclosure further provides methods for contacting an isolated cancer cell characterized by nucleolar hypertrophy with a test sample or substance that can reduce the nucleolar hypertrophy. One benefit to the method of screening disclosed herein can be the identification of test samples or substances capable of reducing nucleolar hypertrophy. Another benefit to the method of screening disclosed herein can be the identification of those combinations of test samples, substances, or combinations or series thereof, which are suitable or optimal for treating specific cancers in patients.